Role of renal cortical neovascularization in experimental hypercholesterolemia

Hypertension

Volumn 50, Issue 4, 2007, Pages 729-736

  Chade, Alejandro R ^a,b   Krier, James D ^a   Galili, Offer ^a   Lerman, Amir ^a   Lerman, Lilach O ^a,c  

^a Mayo Clinic College of Medicine   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Hypercholesterolemia; Inflammation; Kidney; Microcirculation; Thalidomide

Indexed keywords

BETA3 INTEGRIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIUM; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HYPERCHOLESTEROLEMIA; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLOMERULAR FILTRATION RATE; HYPERCHOLESTEROLEMIA; INFLAMMATION; KIDNEY CORTEX; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; REGIONAL BLOOD FLOW; SWINE; THALIDOMIDE;

EID: 34548835228     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.093989     Document Type: Conference Paper

References (47)

1. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000. Circulation. 2004;109:320-323.
4. Bax L, van der Graaf Y, Rabelink AJ, Algra A, Beutler JJ, Mali WP. Influence of atherosclerosis on age-related changes in renal size and function. Eur J Clin Invest. 2003;33:34-40.
5. Chade AR, Mushin OP, Zhu X, Rodriguez-Porcel M, Grande JP, Textor SC, Lerman A, Lerman LO. Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005;46:772-779.
6. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, Napoli C, Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165-1171.
7. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, Sawamura T, Textor SC, Lerman A, Lerman LO. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:1295-1301.
8. Chade AR, Bentley MD, Zhu X, Rodriguez-Porcel M, Niemeyer S, Amores-Arriaga B, Napoli C, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol. 2004;15:1816-1825.
9. Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol. 1995;6:190-195.
10. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061.
11. Chade AR, Krier JD, Textor SC, Lerman A, Lerman LO. Endothelin-A receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17:3394-3403.
12. Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet. 2004;43:311-327.
13. Sze DM, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr Cancer Drug Targets. 2006;6:325-331.
14. Zhang N, Ahsan MH, Zhu L, Sambucetti LC, Purchio AF, West DB. NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation. J Biol Chem. 2005;280:21400-21408.
15. Yasui K, Kobayashi N, Yamazaki T, Agematsu K. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des. 2005;11:395-401.
16. Yagyu T, Kobayashi H, Matsuzaki H, Wakahara K, Kondo T, Kurita N, Sekino H, Inagaki K, Suzuki M, Kanayama N, Terao T. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab. 2005;90:3017-3021.
17. Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant. 2003;18:703-709.
18. Chade AR, Best PJ, Rodriguez-Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int. 2003;64:962-969.
19. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, Lerman A, Lerman LO. Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens. 2003;16:111-115.
20. Feldstein A, Krier JD, Sarafov MH, Lerman A, Best PJ, Wilson SH, Lerman LO. In vivo renal vascular and tubular function in experimental hypercholesterolemia. Hypertension. 1999;34:859-864.
21. Krier JD, Ritman EL, Bajzer Z, Romero JC, Lerman A, Lerman LO. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol. 2001;281:F630-F638.
22. Chade AR, Rodriguez-Porcel M, Herrmann J, Krier JD, Zhu X, Lerman A, Lerman LO. Beneficial effects of antioxidant vitamins on the stenotic kidney. Hypertension. 2003;42:605-612.
23. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004;15:958-966.
24. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J. 2006;20:1706-1708.
25. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol. 2005;16:1005-1012.
26. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, Lerman LO. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol. 2004;286:F1079-F1086.
27. Zhu XY, Daghini E, Chade AR, Rodriguez-Porcel M, Napoli C, Lerman A, Lerman LO. Role of oxidative stress in remodeling of the myocardial microcirculation in hypertension. Arterioscler Thromb Vasc Biol. 2006;26:1746-1752.
28. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, Lerman LO. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1854-1859.
29. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol. 2004;24:1367-1373.
30. Zhu XY, Daghini E, Rodriguez-Porcel M, Chade AR, Napoli C, Lerman A, Lerman LO. Redox-sensitive myocardial remodeling and dysfunction in swine diet-induced experimental hypercholesterolemia. Atherosclerosis. 2007;193:62-69.
31. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794-807.
32. Zhu XY, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109-2115.
33. Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL, Salahudeen A, Tucker JK, Taylor HA Jr. Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease? Am J Med Sci. 2003;325:340-348.
34. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol. 2000;11:152-176.
35. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation. 2003;108:205-210.
36. Tamilarasan KP, Kolluru GK, Rajaram M, Indhumathy M, Saranya R, Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol. 2006;7:17.
37. Komorowski J, Jerczynska H, Siejka A, Baranska P, Lawnicka H, Pawlowska Z, Stepien H. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy 926 cells. Life Sci. 2006;78:2558-2563.
38. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med. 2006;203:2495-2507.
39. Bruick RK, McKnight SL. Building better vasculature. Genes Dev. 2001;15:2497-2502.
40. Donnahoo KK, Meldrum DR, Shenkar R, Chung CS, Abraham E, Harken AH. Early renal ischemia, with or without reperfusion, activates NFkappaB and increases TNF-alpha bioactivity in the kidney. J Urol. 2000;163:1328-1332.
41. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 2000;98:531-535.
42. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-209.
43. Zhao RZ, Chen X, Yao Q, Chen C. TNF-alpha induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathways. Biochem Biophys Res Commun. 2005;327:985-992.
44. Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR. Endothelin 1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci U S A. 1995;92:2691-2695.
45. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004;43:244-253.
46. Ren Y, Carretero OA, Garvin JL. Mechanism by which superoxide potentiates tubuloglomerular feedback. Hypertension. 2002;39:624-628.
47. Izzedine H, Launay-Vacher V, Deray G. Thalidomide for the nephrologist. Nephrol Dial Transplant. 2005;20:2011-2012.